- Home
- CTNT vs TCRX Comparison
CTNT vs TCRX Comparison
Compare CTNT & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTNT | TCRX |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 75.7M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CTNT | TCRX |
|---|---|---|
| Price | $3.26 | $1.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 168.1M | 1.3M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.74 | 12.28 |
| EPS | N/A | ★ N/A |
| Revenue | $1,288,536.00 | ★ $10,325,000.00 |
| Revenue This Year | $42.49 | N/A |
| Revenue Next Year | $22.22 | $19.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 182.69 | ★ 266.65 |
| 52 Week Low | $0.02 | $0.88 |
| 52 Week High | $4.21 | $2.57 |
Technical Indicators
Market Signals| Indicator | CTNT | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 75.48 | 52.17 |
| Support Level | $1.48 | $0.93 |
| Resistance Level | N/A | $1.21 |
| Average True Range (ATR) | 0.36 | 0.11 |
| MACD | 0.28 | 0.00 |
| Stochastic Oscillator | 72.54 | 39.44 |
Price Performance
Historical ComparisonAbout CTNT Cheetah Net Supply Chain Service Inc.
Cheetah Net Supply Chain Service Inc is a provider of logistics and warehousing services, historically in connection with the sale of parallel-import vehicles sourced in the U.S. to be sold in the PRC market, and more recently for the transportation of other goods between the U.S. and the PRC. Parallel-import vehicles in the PRC refer to automobiles purchased directly from overseas markets and imported for sale outside of the brand manufacturer's official distribution networks. The company operates as single report segment. The company operates in the USA and overseas.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.